Plant compounds from grape seeds, pine bark and cranberries, sold for decades. Effects are real but small: less leg swelling and vein discomfort, fewer repeat bladder infections from the cranberry form, slightly lower blood pressure and cholesterol, and clearer falls in markers of oxidative damage. Memory claims have not survived testing. Main downside is reduced absorption of plant-derived iron. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Home blood pressure (seated) | Below 120/80 mmHg | Primary target and the most responsive endpoint |
| LDL cholesterol | Below 100 mg/dL, or below 70 mg/dL with high cardiovascular risk | Detects the small lipid shift OPCs produce |
| Triglycerides | Below 80 mg/dL | The lipid fraction most responsive to OPCs, especially after age 60 |
| hs-CRP | Below 0.5 mg/L | Tracks the low-grade inflammation signal |
| Ferritin | 50–100 ng/mL for men and postmenopausal women; 40–70 ng/mL for menstruating women | The single marker that detects the main plausible harm |
| Transferrin saturation | 25–35% | Confirms an iron trend before ferritin moves |
| Fasting glucose | 75–86 mg/dL | Detects the small glycemic shift, larger with pine bark than grape seed |
| HbA1c | 4.8–5.3% | Confirms whether any glucose change persists over three months |
| Haemoglobin | 13.5–15.0 g/dL for men; 12.5–14.0 g/dL for women | Catches iron-related anaemia before symptoms appear |
| ALT | 10–26 U/L for men; 9–22 U/L for women | Screens for the rare liver signal seen with concentrated botanical extracts |
| INR (only if on warfarin) | Within the individual's prescribed therapeutic window | Detects additive anticoagulant effect |
Cadence: Home blood pressure weekly for the first four weeks, then monthly. Full laboratory panel at 12 weeks and again at 6 months. Ferritin and complete blood count annually thereafter, or sooner if fatigue appears.